Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
P/E ratio for Enochian Biosciences, Inc. (ENOB)
P/E ratio as of 2023: -1.86
According to Enochian Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.86. At the end of 2022 the company had a P/E ratio of -0.80.
P/E ratio history for Enochian Biosciences, Inc. from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.86 |
| 2022 | -0.80 |
| 2021 | -0.89 |
| 2020 | -8.77 |
| 2019 | -17.09 |
| 2018 | -9.30 |
| 2017 | -11.54 |
| 2016 | -33.77 |
| 2015 | -32.41 |
| 2014 | -18.66 |
| 2012 | -784.80 |
| 2011 | -2056.97 |
| 2010 | 0.00 |